BillionToOne, Inc. Class A Common Stock (BLLN)vsMerck & Company Inc (MRK)
BLLN
BillionToOne, Inc. Class A Common Stock
$97.19
-7.08%
HEALTHCARE · Cap: $4.52B
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 18450% more annual revenue ($65.77B vs $354.54M). MRK leads profitability with a 13.6% profit margin vs 7.0%. MRK trades at a lower P/E of 32.6x. MRK earns a higher WallStSmart Score of 50/100 (D+).
BLLN
Hold40
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BLLN.
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 83.8% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
Trading at 8.8x book value
0.0% earnings growth
ROE of 5.0% — below average capital efficiency
7.0% margin — thin
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BLLN
The strongest argument for BLLN centers on Revenue Growth, Debt/Equity. Revenue growth of 83.8% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : BLLN
The primary concerns for BLLN are Price/Book, EPS Growth, Return on Equity. A P/E of 182.2x leaves little room for execution misses.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
BLLN profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
BLLN is growing revenue faster at 83.8% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 40/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BillionToOne, Inc. Class A Common Stock
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company is headquartered in Menlo Park, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?